Vigil Neuro
Jennifer Muccio, MSA, MBA, is an experienced finance professional currently serving as the Director, Assistant Controller at Vigil Neuroscience since March 2022. Previously, Jennifer held the position of Senior Manager of Accounting Operations at Orchard Therapeutics from September 2019 to March 2022 and was involved in various senior managerial roles in accounting at The RMR Group between December 2016 and September 2019. Jennifer’s career began at Deloitte as an Audit Senior and included roles as Audit Assistant and Audit Intern from January 2012 to December 2016. Early experience includes a position as Junior Portfolio Analyst at Price Financial Group Wealth Management. Educational qualifications include a double master's degree in Accounting and Business Administration from Northeastern University and a Bachelor of Science in Finance from Fairfield University, complemented by foundational studies in Economics and Mathematics at Union College.
This person is not in any offices
Vigil Neuro
Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Their purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. They are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.